Category Archives: Diabetes

DeFronzo, R. A. et al. Type 2 diabetes mellitus. Nat. Rev. Dis. Primers 2015(1), 122 (2015).

Google Scholar

Safiri, S. et al. Prevalence, deaths and disability-adjusted-life-years (DALYs) due to type 2 diabetes and its attributable risk factors in 204 countries and territories, 19902019: Results from the global Burden of disease study 2019. Front. Endocrinol. (Lausanne) 13, 114 (2022).

Article Google Scholar

Jelinek, H. F., Stranieri, A., Yatsko, A. & Venkatraman, S. Data analytics identify glycated haemoglobin co-markers for type 2 diabetes mellitus diagnosis. Comput. Biol. Med. 75, 9097 (2016).

Article CAS PubMed Google Scholar

Mahat, R. K., Singh, N., Arora, M. & Rathore, V. Health risks and interventions in prediabetes: A review. Diabetes Metab. Syndr. Clin. Res. Rev. 13, 28032811 (2019).

Article Google Scholar

Yaribeygi, H., Sathyapalan, T., Atkin, S. L. & Sahebkar, A. Molecular Mechanisms Linking Oxidative Stress and Diabetes Mellitus. Oxid. Med. Cell Longev. 2020 (2020).

Sangwung, P., Petersen, K. F., Shulman, G. I. & Knowles, J. W. Potential role of alterations in mitochondrial function in the pathogenesis of insulin resistance and type 2 diabetes. Endocrinology (United States) 161, 110. https://doi.org/10.1210/ENDOCR/BQAA017 (2021).

Article Google Scholar

Oguntibeju, O. O. Type 2 diabetes mellitus, oxidative stress and inflammation: examining the links. Int. J. Physiol. Pathophysiol. Pharmacol. 11, 4563 (2019).

CAS PubMed PubMed Central Google Scholar

Voigt, A. & Jelinek, H. F. Humanin: A mitochondrial signaling peptide as a biomarker for impaired fasting glucose-related oxidative stress. Physiol. Rep. 4, 15 (2016).

Article Google Scholar

Jelinek, H. F., Helf, C. & Khalaf, K. Human SHC-transforming protein 1 and its isoforms p66shc: A novel marker for prediabetes. J. Diabetes Investig. https://doi.org/10.1111/JDI.13551 (2021).

Article PubMed PubMed Central Google Scholar

Maschirow, L., Khalaf, K., Al-Aubaidy, H. A. & Jelinek, H. F. Inflammation, coagulation, endothelial dysfunction and oxidative stress in prediabetes: Biomarkers as a possible tool for early disease detection for rural screening. Clin. Biochem. 48, 581585 (2015).

Article CAS PubMed Google Scholar

Jacob, S. M., Raimond, K. & Kanmani, D. Associated machine learning techniques based on diabetes based predictions, in 2019 International Conference on Intelligent Computing and Control Systems, ICCS 2019 14451450 (2019) https://doi.org/10.1109/ICCS45141.2019.9065411.

Early Classification of Diabetes | Kaggle. https://www.kaggle.com/datasets/andrewmvd/early-diabetes-classification.

Paleczek, A., Grochala, D. & Rydosz, A. Artificial breath classification using xgboost algorithm for diabetes detection. Sensors 21, 745 (2021).

Article Google Scholar

Zeng, H. et al. Metabolic Biomarkers for Prognostic Prediction of Pre-diabetes: Results from a longitudinal cohort study. Sci. Rep. 7, 112 (2017).

Article Google Scholar

Lim, H., Kim, G. & Choi, J. H. Advancing diabetes prediction with a progressive self-transfer learning framework for discrete time series data. Sci. Rep. 13 (2023).

Fregoso-Aparicio, L., Noguez, J., Montesinos, L. & Garca-Garca, J. A. Machine learning and deep learning predictive models for type 2 diabetes: a systematic review. Diabetol Metab. Syndr. 13 (2021).

Wee, B. F., Sivakumar, S., Lim, K. H., Wong, W. K. & Juwono, F. H. Diabetes detection based on machine learning and deep learning approaches. Multimed. Tools Appl. https://doi.org/10.1007/s11042-023-16407-5 (2023).

Article Google Scholar

Oikonomou, E. K. & Khera, R. Machine learning in precision diabetes care and cardiovascular risk prediction. Cardiovasc. Diabetol. https://doi.org/10.1186/s12933-023-01985-3 (2023).

Article PubMed PubMed Central Google Scholar

Elshawi, R., Al-Mallah, M. H. & Sakr, S. On the interpretability of machine learning-based model for predicting hypertension. BMC Med. Inform. Decis. Mak. 19 (2019).

Khan, M. A. B. et al. Epidemiology of Type 2 diabetes: Global burden of disease and forecasted trends. J. Epidemiol. Glob Health 10, 107111 (2020).

Article PubMed PubMed Central Google Scholar

Sadeghi, S., Khalili, D., Ramezankhani, A., Mansournia, M. A. & Parsaeian, M. Diabetes mellitus risk prediction in the presence of class imbalance using flexible machine learning methods. BMC Med. Inform. Decis. Mak. 22, 113 (2022).

Article Google Scholar

Liu, L. et al. Solving the class imbalance problem using ensemble algorithm: application of screening for aortic dissection. BMC Med. Inform. Decis. Mak. 22 (2022).

Elseddawy, A. I., Karim, F. K., Hussein, A. M. & Khafaga, D. S. Predictive analysis of diabetes-risk with class imbalance. Comput. Intell. Neurosci. 2022 (2022).

Rezvani, S. & Wang, X. A broad review on class imbalance learning techniques. Appl. Soft Comput. https://doi.org/10.1016/j.asoc.2023.110415 (2023).

Article Google Scholar

Barmparis, G. D., Marketou, M. E., Tsironis, G. P., Dritsas, E. & Trigka, M. Data-driven machine-learning methods for diabetes risk prediction. Sensors 22, 5304 (2022).

Article Google Scholar

Azad, C. et al. Prediction model using SMOTE, genetic algorithm and decision tree (PMSGD) for classification of diabetes mellitus. Multimed. Syst. 28, 12891307 (2022).

Article Google Scholar

Roy, K. et al. An enhanced machine learning framework for type 2 diabetes classification using imbalanced data with missing values. Complexity 2021 (2021).

Feng, X., Cai, Y. & Xin, R. Optimizing diabetes classification with a machine learning-based framework. BMC Bioinform. 24 (2023).

Tasin, I., Nabil, T. U., Islam, S. & Khan, R. Diabetes prediction using machine learning and explainable AI techniques. Healthc. Technol. Lett. 10, 110 (2023).

Article PubMed Google Scholar

Bellinger, C., Sharma, S. & Japkowicz, N. One-class versus binary classification: Which and when? in Proceedings - 2012 11th International Conference on Machine Learning and Applications, ICMLA 2012 vol. 2 102106 (2012).

Perera, P., Oza, P. & Patel, V. M. One-class classification: A survey. (2021).

Kang, S. Using binary classifiers for one-class classification. Expert Syst. Appl. 187 (2022).

Seliya, N., Abdollah Zadeh, A. & Khoshgoftaar, T. M. A Literature Review on One-Class Classification and Its Potential Applications in Big Data. Journal of Big Data vol. 8 (Springer, 2021).

Lpez-De-Ipia, K., Faundez-Zanuy, M., Sole, J., Zelarin, F. & Calvo, P. Multi-Class versus One-Class Classifier in Spontaneous Speech Analysis Oriented to Alzheimer Disease Diagnosis.

Vasighizaker, A., Sharma, A. & Dehzangi, A. A novel one-class classification approach to accurately predict disease-gene association in acute myeloid leukemia cancer. PLoS ONE 14 (2019).

Liu, X., Ouellette, S., Jamgochian, M., Liu, Y. & Rao, B. One-class machine learning classification of skin tissue based on manually scanned optical coherence tomography imaging. Sci. Rep. 13 (2023).

Argaw, P. N., Kushner, J. A., Kohane, I. S. & Paulson, H. J. A. Unsupervised Anomaly Detection to Characterize Heterogeneity in Type 2 Diabetes. in AMIA Jt Summits Transl Sci Proc 3241 (2023).

Fang, J. et al. Anomaly detection of diabetes data based on hierarchical clustering and CNN. in Procedia Computer Science vol. 199 7178 (Elsevier B.V., 2021).

Fitriyani, N. L. et al. Prediction Model for Type 2 Diabetes using Stacked Ensemble Classifiers. in 2020 International Conference on Decision Aid Sciences and Application, DASA 2020 399402 (Institute of Electrical and Electronics Engineers Inc., 2020). https://doi.org/10.1109/DASA51403.2020.9317090.

Dharmarathne, G., Jayasinghe, T. N., Bogahawaththa, M., Meddage, D. P. P. & Rathnayake, U. A novel machine learning approach for diagnosing diabetes with a self-explainable interface. Healthc. Analyt. 5 (2024).

Hendawi, R., Li, J. & Roy, S. A mobile app that addresses interpretability challenges in machine learningbased diabetes predictions: survey-based user study. JMIR Form Res 7 (2023).

Jakka, A. & Vakula Rani, J. An Explainable AI Approach for Diabetes Prediction. in Lecture Notes in Networks and Systems vol. 565 LNNS 1525 (Springer Science and Business Media Deutschland GmbH, 2023).

Jia, W. Standardising HbA1c-based diabetes diagnosis: Opportunities and challenges. Expert Rev. Mol. Diagn. 16, 343355 (2016).

Article CAS PubMed Google Scholar

Dorcely, B. et al. Novel biomarkers for prediabetes, diabetes, and associated complications. Diabetes Metab. Syndr. Obes. 10, 345361 (2017).

Article CAS PubMed PubMed Central Google Scholar

Wong, C. W. Vitamin B12 deficiency in the elderly: Is it worth screening?. Hong Kong Med. J. 21, 155164 (2015).

CAS PubMed Google Scholar

Australian Institute of Health and Welfare. Diabetes: Australian Facts, Summary. Diabetes https://www.aihw.gov.au/reports/diabetes/diabetes/contents/summary (2023).

Pouvreau, C., Dayre, A., Butkowski, E. G., De Jong, B. & Jelinek, H. F. Inflammation and oxidative stress markers in diabetes and hypertension. J. Inflamm. Res. 11, 6168 (2018).

Article CAS PubMed PubMed Central Google Scholar

Venkatraman, S., Yatsko, A., Stranieri, A. & Jelinek, H. F. Missing data imputation for individualised CVD diagnostic and treatment. Comput. Cardiol. 2010(43), 349352 (2016).

Google Scholar

Nwose, E. U., Jelinek, H. F., Richards, R. S. & Kerr, P. G. Changes in the erythrocyte glutathione concentration in the course of diabetes mellitus. Redox Rep. 11, 99104 (2006).

Article CAS PubMed Google Scholar

Zhao, J. et al. Triglyceride is an independent predictor of type 2 diabetes among middle-aged and older adults: A prospective study with 8-year follow-ups in two cohorts. J. Transl. Med. 17 (2019).

Abdul-Ghani, M. A. & DeFronzo, R. A. Plasma glucose concentration and prediction of future risk of type 2 diabetes. Diabetes care vol. 32 Suppl 2. https://doi.org/10.2337/dc09-s309 (2009).

Ganz, M. L. et al. The association of body mass index with the risk of type 2 diabetes: A case-control study nested in an electronic health records system in the United States. Diabetol. Metab. Syndr. 6 (2014).

Tony Liu, F., Ming Ting, K. & Zhou, Z.-H. Isolation forest ICDM08. ICDM (2008).

Carletti, M., Terzi, M. & Susto, G. A. Interpretable anomaly detection with DIFFI: Depth-based feature importance of isolation forest. Eng. Appl. Artif. Intell. 119 (2023).

Butkowski, E. G. & Jelinek, H. F. Hyperglycaemia, oxidative stress and inflammatory markers. Redox Rep. 22, 257264 (2017).

Article CAS PubMed Google Scholar

Lagman, M. et al. Investigating the causes for decreased levels of glutathione in individuals with type II diabetes. PLoS ONE 10, 119 (2015).

Article Google Scholar

Al-Goblan, A. S., Al-Alfi, M. A. & Khan, M. Z. Mechanism linking diabetes mellitus and obesity. Diabetes Metab. Syndr. Obes. 7, 587591 (2014).

Article PubMed PubMed Central Google Scholar

Leitner, D. R. et al. Obesity and type 2 diabetes: Two diseases with a need for combined treatment strategies - EASO can lead the way. Obes. Facts 10, 483492 (2017).

Article PubMed PubMed Central Google Scholar

Akbari, M. & Hassan-Zadeh, V. IL-6 signalling pathways and the development of type 2 diabetes. Inflammopharmacology 26, 685698. https://doi.org/10.1007/s10787-018-0458-0 (2018).

Article CAS PubMed Google Scholar

Ene, C. V., Nicolae, I., Geavlete, B., Geavlete, P. & Ene, C. D. IL-6 Signaling link between inflammatory tumor microenvironment and prostatic tumorigenesis. Analyt. Cell. Pathol. https://doi.org/10.1155/2022/5980387 (2022).

Article Google Scholar

Mirmira, R. G. et al. Interleukin-6 reduces B-cell oxidative stress by linking autophagy with the antioxidant response. in Diabetes vol. 67 15761588 (American Diabetes Association Inc., 2018).

Halimi, A. et al. The relation between serum levels of interleukin 10 and interferon-gamma with oral candidiasis in type 2 diabetes mellitus patients. BMC Endocr. Disord. 22 (2022).

Ayelign, B. et al. Association of IL-10 ( 1082 A/G) and IL-6 ( 174 G/C) gene polymorphism with type 2 diabetes mellitus in Ethiopia population. BMC Endocr. Disord. 21 (2021).

Abhilasha et al. Downregulation of interleukin-10 receptor (IL-10R) along with low serum IL-10 levels in newly diagnosed type 2 diabetes mellitus patients. Gene Rep. 24 (2021).

Carlini, V. et al. The multifaceted nature of IL-10: regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions. Front. Immunol. https://doi.org/10.3389/fimmu.2023.1161067 (2023).

Article PubMed PubMed Central Google Scholar

Jelinek, H., Jamil, D. & Al-Aubaidy, H. Impaired fasting glucose & 8-iso-prostaglandin F2 in diabetes disease progression. Br. J. Med. Med. Res. 4, 52295237 (2014).

Article Google Scholar

Schttker, B., Xuan, Y., Go, X., Anusruti, A. & Brenner, H. Oxidatively damaged DNA/RNA and 8-isoprostane levels are associated with the development of type 2 diabetes at older age: Results from a large cohort study. Diabetes Care 43, 130136 (2020).

Go here to read the rest:
Exploratory risk prediction of type II diabetes with isolation forests and novel biomarkers | Scientific Reports - Nature.com

Despite medical cannabis in the US dating back more than 3 decades, the legalization movement in the last decade means millions and millions of US adults now have access to cannabis, for both medical and recreational purposes.

However, with this boom in use, concerns regarding the health effects of cannabis use have become a greater focal point of discussion among medical circles. According to a 2023 study in JAMA Network Open, 17% of a 175,000-patient cohort of adults reported cannabis use in the previous 3 months and 34.7% of those individuals met the criteria for moderate to high risk for cannabis use disorder.1

At the 84th American Diabetes Association Scientific Sessions, Halis Akturk, MD, associate professor of medicine and pediatrics at the Barbara Davis Center for Diabetes at the University of Colorado, led a session titled The Highs and Lows of Cannabis Use in DiabetesBehavioral and Psychosocial Considerations. Based in Colorado, Akturk has a unique view from the frontlines of research and real-world practice as Colorado was among the first states to allow for both medical and nonmedical cannabis use.

In the past 5 years, Akturk has published numerous studies detailing the effects of cannabis use with type 1 diabetes. In 2019, a study from Akturk in JAMA Internal Medicine evidenced the elevated risk of diabetic ketoacidosis among adults with type 1 diabetes using cannabis receiving care at the Barbara Davis Center for Diabetes. Building o this research, a similar study published in Diabetes Care in 2020 confirmed a similar trend using data from the T1D Exchange clinical registry. In 2022, Akturk led an additional study providing clinicians with an overview of the differences in presentation between diabetic ketoacidosis and hyperglycemic ketosis due to cannabis hyperemesis syndrome.2,3,4

At ADA 2024, we sat down with Akturk to learn more about this emerging space, what additional risks are associated with cannabis use in adults with and without type 1 diabetes, and what questions hears most often from his colleague regarding the topic.

HCPLive: What is the prevalence of cannabis use among people with type 1 diabetes and what are the primary reasons cited for use?

Akturk: In Colorado, we have the one of the highest rates of cannabis users with type one diabetes. So, we did a survey study a couple years ago and we asked the adults with type one diabetes: "Have you been using the cannabis or have you ever used the cannabis in the last 12 months?". In the results, there were about 30% of the patients in the adult clinic with type 1 diabetes that were at least used once cannabis in the last one year. The reasons for use were multiple, with about 75% of the people were using recreational reasons and 25% of the people were using medicinal reasons. In some states, you can just get a medicinal card for different indications. This was relatively a high use in our community for type 1 diabetes.

HCPLive: What are some of the chief concerns about how the effects of cannabis use manifest among patients with type 1 diabetes?

Akturk: Our previous research showed that the people who are using cannabis have an increased risk for diabetic ketoacidosis when they have type 1 diabetes. This was a local study we did a couple of years ago in JAMA, where we were trying to find out the reasons for that. Then we went to the T1D Exchange data and we looked to see if we can confirm our study results. We confirmed that the people who are using cannabis, after adjustment for the other things like pump use, age, diabetes, duration and other confounders, were at an increased for diabetic ketoacidosis.

As a next step, we realized that these people have a different the metabolic profile when they present to ER with the diabetic ketoacidosis symptoms. In other research, what we did is we looked at their metabolic profiles and their labs to compared people who are using cannabis and not using it. So, we did an objective study, and we looked at their urine drug screen use. If somebody's urine drug screen is positive for cannabis, we consider this person is using and, if it's not that, we consider that as not using it.

We found very significant differences in terms of the labs at presentation. We showed that these same people are also getting hyperglycemia, they are getting ketosis, and they have an onion gap. They also present to the ER with nausea and vomiting. But the main difference was the pH and the bicarb. So, their pH was more than 7.4 and their bicarb was more than 15. So, in DKA, there should be pH should be less than 7.3 and bicarb should be less than 15. So, we call them as a different entity, as hyperglycemic ketosis related to the cannabis hyperemesis syndrome.

HCPLive: When should providers approach discussions around cannabis use among patients with type 1 diabetes?

Akturk: I think we should educate people about cannabis at the type 1 diabetes diagnosis. We have a structured plan for the sick day management for alcohol and we added structures for cannabis education in the type 1 diabetes care program at the Barbara Davis Center. If there is a new patient, I suggest the providers, especially the endocrinologist, to discuss the cannabis with them at their first visit. If they have some frequent visits related to the ER visits and there are some frequent diabetic ketosis episodes, I suggest asking them if they use cannabis or not.

Editor's note: these transcripts have been edited for length and clarity.

Disclosures of interest for Akturk include REMD, Dexcom, Senseonics, and Eli Lilly and Company.

References:

Read more here:
What to Know About Cannabis Use and Diabetes, with Halis Akturk, MD - MD Magazine

With its advanced algorithm that provides autocorrections every 5 minutes, the latest data demonstrated that the MiniMed 780G system decreased rates of early morning hyperglycemia, known asdawn phenomenon, and improved overnight sleep

DUBLIN and ORLANDO, Fla., June 21, 2024 /PRNewswire/ -- Medtronic plc(NYSE: MDT),a global leader in healthcare technology, is presenting a comprehensive body of new data at the American Diabetes Association's (ADA) 84thScientific Sessions that showcases the benefits of the MiniMed 780G system. New data shows how the system addresses hyperglycemia and nighttime burden, adding to the established body of evidence that demonstrates the system's ability to tackle unique and burdensome challenges of diabetes, such as managing highs and meal-time management or carb counting, while also mirroring outcomes across a wide-ranging patient population.

Tackling hyperglycemia to improve long-term health with type 1 diabetesAmong the burdens of living with diabetes, hyperglycemia can often be overshadowed by hypoglycemia. Yet, in the U.S., only 26% of people living with diabetes achieve HbA1c levels of <7.0%.1Reducing the time spent with high blood sugars continues to be a significant unmet need as it can lead to serious health problems impacting multiple organs.2 For children, prolonged highscan have adverse effects on memory, IQ, executivefunctioning, and learning.3

One cause of high blood sugars is the dawn phenomenon, an increase in glucose levels in the early morning.4 This can be a common occurrence for those living with diabetes and may add to feelings of frustration with diabetes. An encouraging new retrospective analysis of real-world data (n= 6026) showed that this morning peak was nearly eliminated for users who upgraded from the MiniMed 770G system to the MiniMed 780G system. The data assessed the elevation of sensor glucose levels >20 mg/dL from 3 - 6 a.m. compared to 12 3 a.m. at least 30% of the nights. The transition from the MiniMed 770G system to the MiniMed 780G system decreased dawn phenomenon rates from 12.2% to 4.5%. Time in Range also increased from 87.7% to 91.4% from 12 6 a.m., which is consistent with dawn phenomenon trends.

Early and consistent management of hyperglycemia is critical as it has protective effects on the body that can last for decades.5 "For those living with type 1 diabetes, dawn phenomenon can be a stressful occurrence that feels out of one's control," explained Robert Vigersky, MD, Chief Medical Officer, Medtronic Diabetes. "The introduction of the MiniMed 780G system has made it easier to maintain target glucose range with less effort to protect against hyperglycemia.6,7 It's been an absolute gift for my patients who have struggled with stubborn highs throughout their diabetes journey."

Reducing nighttime burden For individuals living with type 1 diabetes, CGM-generated alerts and the need to deliver manual boluses disrupt sleeping through the night adding to the burden of diabetes. The MiniMed 780G system is designed to reduce the burden of diabetes throughout the day and night. Additional real-world data from a retrospective analysis presented at ADA (n=8019; <7 y/o, previously on the MiniMed 770G system who had greater than 14 nights on both systems) demonstrated that users had fewer overnight sleep interruptions and Time in Range improvements as a result of the automatic adjustments in insulin and correction of glucose levels every 5 minutes, including during sleep. With the MiniMed 780G system, nighttime alerts decreased 45% for all users and 55% for those who used recommended optimal settings. Additionally, uninterrupted sleep, a greatly desired outcome for those living with diabetes, increased by 30 and 36 minutes per night, respectively. These results add to the diabetes burden reduction that MiniMed 780G system users experience with an advanced algorithm with frequent, every 5-minute autocorrections.

The continued evolution of the MiniMed 780G system to reduce burdenAlong with evidence on the currently available MiniMed 780G system, additional data will be presented on the next iteration of the system,* which aims to further reduce diabetes management burden through its design. The system is intended to be paired with the Simplera Sync sensor, a disposable, all-in-one continuous glucose monitor (CGM) designed to require no overtape.

A 24-site, single arm study evaluated the use of the next iteration of the MiniMed 780G system algorithm paired with the Simplera Sync sensor. Results were promising across all clinical outcomes metrics including Time in Range (TIR), Time in Tight Range (TITR) and Time Above Range (TAR), compared to the run-in group where hybrid closed loop (auto basal only) or open-loop delivery was used. The study included the use of recommended optimal settings (ROS) (100 mg/dL set target with an active insulin time of 2 hours) related to TIR, TITR, and TAR.

"The MiniMed 780G system has firmly established itself as a proven automated insulin delivery system," said study investigator Gregory Forlenza, MD, professor and pediatric endocrinologist at the Barbara Davis Center. "With the next iteration of the system and this next-generation Simplera Sync sensor, the overall experience for people living with type 1 diabetes could be enhanced and may prove to be a compelling option for diabetes management particularly when leveraged in combination with recommended optimal settings."

The MiniMed 780G system** is currently available for ages 7 and above in over 100 countries globally and will be launching with the Simplera Sync sensor in parts of Europe in late July. Currently, Simplera Sync is investigational and not approved for commercial use in the U.S.*

Safety and Glycemic Outcomes Using the MiniMed 780G system with an All-in-One Disposable Sensor with Transmitter 3-month study period (n=109, ages 7-17; n=107, ages 18-80)

Youths

(ages 7-17)

Adults

(ages 18-80)

Run-in (N=112)

Study (N=109)

ROS (N=41)

Run-in (N=110)

Study (N=107)

ROS (N=44)

Time in Smart Guard, %

14.531.3

93.511.3

96.93.1

33.240.3

96.66.6

97.53.7

Mean SG, mg/dL

180.427.1

154.417.6

149.015.3

161.018.7

142.212.8

136.512.0

Percentage of time spent at glucose ranges

<70 mg/dL

(% TBR)

1.61.7

1.91.4

1.91.2

1.71.9

1.51.4

1.71.4

70-140 mg/dL

(% TITR)

32.114.1

49.29.7

52.79.2

39.213.0

56.110.5

61.69.9

70-180 mg/dL

(% TIR)

54.415.7

71.49.9

74.79.3

66.512.6

80.28.1

83.87.4

>180 mg/dL

(% TAR)

44.016.1

26.710.1

23.39.4

31.813.1

18.28.4

14.57.7

Caption: Glycemic metrics and insulin delivered during youth and adult MiniMed 780G system investigational use with the disposable all-in-one Simplera Sync sensor

To view this data at the 84thAmerican Diabetes Association (ADA) Scientific Sessions inOrlando, Florida, view the company's previous announcement here for presentation times.

About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission to alleviate pain, restore health, and extend life unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit http://www.Medtronic.com and follow Medtronic on LinkedIn.

About Medtronic Diabetes (www.medtronicdiabetes.com) Medtronic Diabetes is on a mission to alleviate the burden of diabetes by empowering individuals to live life on their terms, with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

*Investigational. Not approved by the FDA for any use and not commercially available in the US.

**MiniMed 780G system is for type 1 ages 7 and over. Prescription required. WARNING: Do not use SmartGuard feature for people who require less than 8 units or more than 250 units of insulin/day. For details, seehttps://bit.ly/780gRisks

Refers to auto correct, which provides bolus assistance. Can deliver all auto correction doses automatically without user interaction, feature can be turned on and off.

Refers toSmartGuard feature. Individual results may vary.

Contacts:

Ashley Patterson

RyanWeispfenning

Public Relations

Investor Relations

+1 (818) 576-3025

+1 (763) 505-4626

SOURCE Medtronic plc

Go here to read the rest:
New MiniMed 780G system data demonstrates ability to address persistent blood sugar challenges for people with ... - PR Newswire

By: Staff Writer | June 21, 2024 | 5 min. read| Share Article Summary

The Diabetes Research Institute (DRI) at the University of Miami Miller School of Medicine unveiled an innovative approach at the American Diabetes Associations (ADA) 84th Scientific Sessions that highlights the potential of human, stem cell-derived islets combined with an immunomodulatory microgel to reverse Type 1 diabetes (T1D).

This technology was developed to enable pancreatic islet cell replacement in the allogeneic setting (from a donor to an unrelated recipient) without the need for chronic, systemic immunosuppression.

The collaborative effort was spearheaded by Giacomo Lanzoni, Ph.D., a Miller School research assistant professor in biochemistry and molecular biology, with teams from iTolerance, Inc., and Kadimastem, Ltd. The research demonstrates that the combination of iTOL-100 engineered microgel developed by iTolerance, Inc., and IsletRx stem cell-derived islets developed by Kadimastem, Ltd., can effectively restore normoglycemia in a model of diabetes.

Our observations highlight the transformative potential of combining stem cell-derived islets with an immunomodulatory microgel, Dr. Lanzoni said. This approach could enable transplantation across the allogeneic barrier, offering a scalable and sustainable solution for T1D, and could enhance the safety and long-term efficacy of islet cell transplantation.

The Fast Track Center for Testing at the DRI Cell Transplant Center continues to serve as a key shared resource to validate emerging technologies towards a cure for diabetes, said Camillo Ricordi, M.D., director of the Cell Transplant Center and director emeritus at the Diabetes Research Institute as well as chief in the Division of Cellular Transplantation at the Miller School. We hope to continue to be of assistance towards the identification of reliable and potentially unlimited stem cell-derived islet sources for transplantation, which may one day be able to replace the limited availability of pancreas-derived islets from multiorgan donors, when lifelong recipient immunosuppression will no longer be required.

The studys key findings indicate that this combination therapy reverses diabetes and preserves the functional integrity of the transplanted stem cell-derived islets.

iTOL-100, an immunomodulatory microgel designed to eliminate the need for chronic systemic immunosuppression and shown to induce local immune acceptance of transplanted islets, was found to be compatible with stem cell-derived islets.

IsletRx, a preparation of human, stem cell-derived islets, is a scalable and virtually unlimited source of insulin-producing cells and could address the critical shortage of donor islets for transplantation.

The transplantation procedure is performed in a retrievable site, ensuring the possibility of graft retrieval through a minimally invasive surgery, if needed.

The study reports reversal of disease in a chemically induced model of diabetes, with comparable efficacy of IsletRx in the presence or absence of iTOL-100, indicating a lack of toxicity from the microgel.

iTolerance is pleased to co-sponsor the project at the Diabetes Research Institute toward a functional cure of T1D through the combination of human stem cell-derived insulin producing islet cells together with our iTOL-100 proprietary immunomodulator, said Anthony Japour, M.D., CEO of iTolerance, Inc. Removing the need for life-long toxic immunosuppressive agents in islet transplantation is a common goal among those working toward a cure for T1D through transplantation without immunosuppression.

Our collaboration with iTolerance opens an innovative and world-first avenue for transplanting pancreatic islet cells into people with diabetes without the need for full suppression of the immune system, which is required today in organ transplants, said Michel Revel, M.D., Ph.D., chief scientist at Kadimastem, Ltd. Our company produces high-quality pancreatic islet cells. The joint data collected by us proves the possibility of combining our cells with the material that locally prevents the rejection of the implant developed by our project partner iTolerance. Having successfully completed an Interact meeting with the FDA, the two companies are moving together to the pre-IND submission stage.

IsletRx is comprised of clinical-grade clusters of human pancreatic islet like cells (ILCs) with the ability to secrete insulin. IsletRx cells can detect the sugar levels in the body and produce the required amounts of insulin and glucagon. The companys technology can select and enrich only the highest functioning and purest islet cells from the population of pluripotent stem cells, which enables the maximum therapeutic effect.

The project was supported in part by iTolerance, Inc., Kadimastem, Ltd., grants funded by the Breakthrough T1D Foundation (formerly known as JDRF) and the Israel-U.S. Binational Industrial Research (BIRD) Foundation.

Tags: Camillo Ricordi, diabetes, Diabetes Research Institute, DRI, giacomo lanzoni, islet cell transplantation, pancreas

Original post:
Diabetes Research Institute Announces Breakthrough Transplantation Approach for the Treatment of Type 1 Diabetes ... - University of Miami

Tzield (teplizumab) was approved in2022, becoming the first treatment to delay the onset of type 1 diabetes. Currently, Tzield is for people aged 8 and up who have stage 2type 1 diabetes meaning they have two or more autoantibodies and abnormal blood sugar, but not high enough to be stage 3 which means the person already has type 1 diabetes.

What if Tzield could be used later on, once someone has been diagnosed with diabetes, to prevent progression of the disease?

Since Tzields approval, researchers like Dr. Kevan Herold, professor of immunobiology and of medicine and an endocrinologist at Yale University, have begun testing the medication for different stages of type 1 diabetes. Indeed, previousresearch by Herold and colleagues has suggested that Tzield might preserve beta cells.

If Tzield is able to prevent progression in those with newly diagnosed diabetes, it could potentially be a big improvement. For instance, this could lead to lower insulin or no insulin , meaning fewer or no injections and a lower risk ofhypoglycemia (low blood sugar). Its possible this could even translate to longer-term benefits, such as a lower risk ofdiabetes complications.

Tzield works by attaching to and modifying T-cells, a type of immune cells that destroy the insulin-producing beta cells in type 1 diabetes. In doing so, Tzield helps interrupt the immune systems attack on beta cells and delayed the onset of type 1 diabetes in a clinical trial by two to three years.

ThePROTECT study investigated whether treatment with Tzield could prevent disease progression in people newly diagnosed with type 1 diabetes. The study included 328 children and teens, ages 8 to 17 years old, who had been diagnosed with diabetes for up to 6 weeks. Participants were randomly assigned to receive two courses of Tzield treatment or a placebo.

In the original PROTECT trial, researchers found that Tzield led to significantly greater preservation of beta cells compared to placebo.

The problem, Herold said, was that the PROTECT study was done during theCovid-19 pandemic, which threw a wrench into the conduct of the trial. As a result of the pandemic, some participants were unable to receive a full course of Tzield.

Thecurrent analysis specifically looked at participants who strictly followed the treatment protocol, meaning that they received 80% or more of the prescribed dose of Tzield. Participants who received less than 80% of the recommended dose, took prohibited medications (such as steroids or vaccines), or became pregnant were not included in this analysis.

To measure how well Tzield preserved beta cells, the researchers looked at a metric called C-peptide. C-peptide is made by beta cells during insulin production and is found in blood or urine tests. C-peptide is commonly used in studies of type 1 diabetes, such as in research investigating the cell therapy Lantidra and Vertexs VX-880 stem cell treatment. A higher C-peptide level indicates that more beta cells are working and producing insulin.

This analysis included 275 participants: 180 were randomly assigned to receive Tzield, and 95 were randomly assigned to the placebo. At the start of the study, participants had an average age of 12, BMI of 19, and an A1C of 9%.

At week 78:

Despite these findings, A1C levels were comparable between the Tzield and placebo groups.

An additional analysis found that timing of the second course of Tzield whether participants received it at 6 months as recommended, or at 12 months did not affect preservation of beta cells, Herold noted. This is an encouraging finding, as it suggests participants whose dosing was interrupted by the pandemic were still able to reap the benefits of Tzield.

This analysis of the PROTECT study showed that participants who received Tzield as directed had significantly greater beta cell preservation and time in range. Participants treated with Tzield also had lower insulin needs, which may have contributed to the lower risk of severe hypoglycemia.

These findings suggest that Tzield may be useful in preventing progression of type 1 diabetes in those newly diagnosed with the condition. Note that this study only investigated children and teens, so more research is needed, including whether Tzield is beneficial for the growing population of adults newly diagnosed with type 1 diabetes.

Overall, this analysis suggests that Tzield may be beneficial across a wider time frame not just in stage 2 type 1 diabetes. Hopefully, future research will determine the best time for participants to receive Tzield.

I think the general impression at this point is that theres probably a window of treatment opportunity that is sometime around the rapid decline in beta cell function that occurs in the peri-diagnosis period, Herold said.

Learn more about new treatments for type 1 diabetes:

Read the original here:
Could Tzield Help Children Newly Diagnosed with Diabetes? - diaTribe Foundation

Gdask, Poland 24 June 2024 PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, today announces that its polyclonal Treg cell therapy PTG-007 demonstrated significant insulin secretion restoration in early-onset type-1 diabetes (T1D) patients, as well as a longer period of disease remission compared to a control group receiving standard-of-care, in a long-term clinical study into the safety and efficacy of lead asset PTG-007. The study monitored pediatric patients who received the autologous treatment over a period of 7 to 12 years.

The main findings were:

This long-term study is a confirmation that the significant efficacy we found in our Phase 1/2 clinical trial for PTG-007 is sustainable over the long term. At PolTREG, we believe that PTG-007 has the potential to prevent type-1 diabetes, freeing patients of the life-long burden of having to take frequent insulin injections, and the serious long-term complications of the disease. The results of this study are an important step in that direction, said Prof Piotr Trzonkowski, Chief Executive Officer of PolTREG.

With the study, PolTREG has fulfilled a requirement by the European Medicines Agency to confirm the safety of Treg therapies at least 5 years after their administration. To the best of PolTREGs knowledge, no other company currently can show similar long-term safety results of Treg therapy in T1D. This is a significant competitive advantage, and paves the way for the company to launch a pivotal Phase 2/3 study of PTG-007 to treat T1D.

PolTREG is currently seeking partnership funding for this pivotal trial, the final step required before seeking regulatory authorization for commercialisation. The company will submit the data for a peer-reviewed scientific publication in the near future. Later this year, we will also be launching a Phase 2 study in presymptomatic patients, children who are not yet showing any symptoms but in whom we are now able to detect diabetes, Prof Trzonkowski said.

PolTREG holds one of the largest and most advanced pipelines for Treg therapies for autoimmune disease, developing both polyclonal and engineered therapies. Its lead candidate, PTG-007, an autologous polyclonal Treg treatment, is in mid-stage clinical studies for T1D and multiple sclerosis (MS). Next year, PolTREG expects to start a first-in-human trial of its engineered CAR-Tregs for treatment of two neurodegenerative diseases, MS and amyotrophic lateral sclerosis (ALS). The company also is in preclinical development with two further types of engineered Treg cells.

PolTREG manufactures all its Treg therapeutics at its own GMP-certified manufacturing facility. It is the first company in the world to administer Treg therapies to patients, and, under a hospital exemption valid in Poland, the first to start receiving revenues from a Treg therapeutic for autoimmune disease. Its GMP manufacturing facility is one of Europes largest and most advanced, boasting over 2,100 sqm of laboratory space, including 15 production lines. PolTREG has the option to substantially expand the facility to accommodate manufacturing of next-generation engineered therapies and cell therapies. It can ship its wide range of cellular therapy products across Europe within 24 hours.

About PolTREG PolTREG is a global leader in developing autoimmune therapies based on T-regulatory cells (Tregs). Its lead product, PTG-007, autologous Treg treatment for early-onset Type-1 Diabetes (T1D) is ready for Phase 2/3 clinical testing, for which the company is seeking a partnership. The company will launch Phase 2 trials for PTG-007 to treat Multiple Sclerosis (MS) in the second half of 2024, for RRMS and PPMS. PolTREG also has engineered Tregs, including CAR-Tregs, antigen-specific Tregs and TCR-Tregs, in the preclinical stage. PolTREG has completed four clinical trials with more than 100 patients treated with Tregs.

For more information please visit http://www.poltreg.com.

PolTREG S.A. Prof Piotr Trzonkowski Chief Executive Officer ir@poltreg.com +48 512 532 401

Media Relations Douwe Miedema Cohesion Bureau +352 621 562 764 douwe.miedema@cohesionbureau.com

Important information The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The company's actual results may differ materially from those predicted by the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

See more here:
PolTREG's type-1 diabetes Treg cell therapy PTG-007 - GlobeNewswire

The FreeStyle Libre 3 continuous glucose monitor. [Image courtesy of Abbott] The Diabetes business unit at Abbott (NYSE:ABT) has gotten off to a hot start in 2024, with some significant developments on the CGM front.

With the recent FDA clearance of two over-the-counter sensors following significant automated insulin pump integrations, 2024 has been full of good news for the company.

Speaking toDrug Delivery Business News at the American Diabetes Association Scientific Sessions in Orlando, Florida, Abbott Diabetes SVP of Commercial Operations, Chris Scoggins, said the company wants to keep that momentum going.

2024 is shaping up to be an exciting year, a good year, Scoggins said. The excitement for us, at least in the U.S., is that were just pushing deeper and deeper into this really big, underserved patient population of people with type 2 diabetes.

As Abbott broadens its patient population, Scoggins said the company is reaching new channels, like primary care, benefitting more people with diabetes, namely type 2. He called it a new chapter in the brand.

Scoggins said the push for the type 2 population is an energizing endeavor.

Something thats important for everbody to understand is, we have much work to do as an industry to really bring to the type 2 population the technologies and brands that are pretty well covered and supplied into that smaller type 1 population, Scoggins explained. Its something that puts a lot of wind in our sails.

Abbott hears patient stories often, he said, highlighting how they benefit from using the FreeStyle Libre CGM platform. According to Scoggins, it helps them see things for the first time that perhaps they failed to understand before.

Using minute-by-minute glucose readings and seeing how lifestyle choices, food choices or activity impacts glucose variability provides things that were previously hidden in a 90-day HbA1c test.

You cant really see that type of variability, Scoggins said. But, when youre doing daily time in range, all of a sudden, those lifestyle choices become very real. Those are the kinds of learnings and insights that the type 2 population can really derive benefit from when using Libre.

At the start of the year, Abbott made great strides in automated insulin delivery, pairing its FreeStyle Libre 2 Plus with Insulets Omnipod 5 in Europe and announcing compatibility with the Tandem Diabetes Care t:slim X2 system in January.

Its a really important segment, Scoggins said. Theres a high medical need for people that have type 1 diabetes and use a pump.

Globally, he explained, more than half a billion people have diabetes. The vast majority fall into the type 2 category, Scoggins said. With FreeStyle Libre, he says Abbott wanted to think about the largest groups of people underserved by diabetes technology. With the push for addressing the type 2 population taking the front seat, the company has now turned some focus toward the type 1 subgroup targeted by automated insulin delivery technology makers.

Now, Scoggins says, its important that Abbott gets it right with regard to automated insulin delivery.

Right now, the company offers the FreeStyle Libre 2 plus, built on the Libre 2 platform, in the U.S. with Tandem. However, it actually started pump connectivity with Libre 3, the latest generation, in Europe, with Ypsomed and CamDiab.

Scoggins said the company feels strongly about the process of working with a pump partner to create an effectively connected, quality, regulated system that everyone feels good about, both for regulatory and technological reasons. Ultimately, the company intends to continue expanding the options for this patient base.

Were going to help the patients we serve and engender the confidence of the endocrinologist, so you know to trust Libre to connect to a pump, Scoggins explained. While we are showing up in the pump space later than some of our competitors, our intent is to not just show up, but to become the brand of choice and the standard of care.

We dont want to just show up and participate. We want to be the reference.

The launch of Lingo effectively a CGM for monitoring health and wellness outside diabetes widens the population Abbott can reach, but, in a diabetes-specific sense, the over-the-counter Libre Rio is yet another major step forward in reaching more patients.

Libre Rio provides monitoring for adults with type 2 diabetes who arent on insulin and manage diabetes through lifestyle modifications. Like the companies prescription CGMs, Libre Riowill rival Dexcoms OTC Stelo for people with type 2 diabetes who do not use insulin.

Theres not a one-product-serves-all solution that we could see meet the needs in the market, Scoggins said. Thats why we offered to separate sensors to serve both of these consumers.

As a research-driven organization, Scoggins says Abbott is always looking to build upon its platforms, like with Rio and Lingo.DVP, Technical Operations, Marc Taub, explained this innovation process last fall at DeviceTalks West.The company also continues development on afirst-of-its kind, all-in-one sensor that measures both glucose and ketone.

Scoggins said the company has been somewhat surprised by the reaction of the medical community and the interest in understanding how that sensor could help people at risk for diabetic ketoacidosis (DKA).

Abbott built this sensor on the Libre 3 form factor. Scoggins said it fits with what FreeStyle Libre stands for, providing functional understanding of the variability of glucose but also visibility into the risk of ketosis. It also improves upon the existing ketone strip which Abbott offers with low utilization of that product. The convenience of having that second measure included in a glucose sensor could set the device apart.

Still in development and not at the stage of commercial discussions yet, the sensor still could garner plenty of attention. Scoggins expects rigorous clinical activity to prepare for regulatory submission and more to come on this front.

More can benefit and that interest in the multi-analyte sensor, I think its just kind of scratching the surface, Scoggins said. Theres so much more we can do.

More here:
Abbott targets type 2 diabetes with 'exciting year' ahead - Drug Delivery Business News

South Africas public health care system has run out of the human insulin pens that it provides to people with diabetes, as the pharmaceutical industry shifts production priorities to blockbuster weight-loss drugs that use a similar device for delivery.

Novo Nordisk, the company that has supplied South Africa with human insulin in pens for a decade, opted not to renew its contract, which expired last month. No other company has bid on the contract to supply 14 million pens for the next three years, at about $2 per pen.

Current manufacturing capacity limitations mean that patients in some countries, including South Africa, may have limited access to our human insulins in pens, said Ambre James-Brown, a spokeswoman for Novo Nordisk. The company did not reply to questions about which other countries are affected.

Novo Nordisks drugs Ozempic and Wegovy, which are widely prescribed in the U.S. for weight loss, are sold in single-use pens produced by many of the same contracted manufacturers who make the multidose insulin pens. A months supply of Ozempic in the United States costs about $1,000, far more than insulin.

Novo Nordisk dominates the global market for insulin in pens and has supplied South Africa since 2014. Eli Lilly, the other major producer, has indicated in recent months that it is struggling to keep up with the significant demand for its weight-loss drug Zepbound.

This is because of the global demand for Ozempic and these drugs, said Khadija Jamaloodien, the director of sector-wide procurement for South Africas health service. Theyre shifting the focus on the more profitable line.

We are having trouble retrieving the article content.

Please enable JavaScript in your browser settings.

Thank you for your patience while we verify access. If you are in Reader mode please exit andlog intoyour Times account, orsubscribefor all of The Times.

Thank you for your patience while we verify access.

Already a subscriber?Log in.

Want all of The Times?Subscribe.

Read more:
South Africa Runs Out of Insulin Pens as Global Supply Shifts to Weight-Loss Drugs - The New York Times

Francisco Pasquel, MD, MPH Credit: Emory University

Use of the Omnipod 5 automated insulin delivery (AID) system decreased median HbA1c from 8.2% to 7.4% in 13 weeks among users with type 2 diabetes, according to results of the SECURE-T2D trial.

Billed as the largest, longest, and most racially diverse study of AID in people with type 2 diabetes to date, results of the SECURE-T2D trial demonstrate provided substantial benefit, including a nearly 5-hour increase in time in range per day, with results of AID use similar across subgroups defined by race/ethnicity, GLP-1 RA use, prior insulin regimen, and pre-study insulin meal dosing method.1,2

Our findings demonstrate substantial improvements in blood glucose outcomes and overall quality of life, highlighting the potential for this innovative technology to transform type 2 diabetes management with automated insulin delivery, said chair of the study Francisco Pasquel, MD, MPH, associate professor of Medicine of Emory University.2 As the largest study of AID therapy in people with type 2 diabetes, we look forward to these results supporting the FDA clearance of Omnipod 5 as a safe and effective therapy for this patient population.

With the receipt of FDA clearance for type 1 diabetes in January 2022, the Omnipod 5 became the first tubeless AID system with smartphone control. As the benefits of diabetes technology has continued to emerge in recent years, an interest in their utility among people with type 2 diabetes has become evident. At the 2024 International Conference on Advanced Technologies & Treatments for Diabetes, Insulet presented data from an 8-week feasibility study among adults with type 2 diabetes confirming the potential of the Omnipod 5 among this patient population.3,4

In SECURE-T2D, which was presented at the 84th American Diabetes Association Scientific Sessions, investigators enrolled 305 individuals from 21 sites across the US. For inclusion, patients were required to be 18 to 75 years of age, have type 2 diabetes, have been on their current insulin regimen for 3 or more months, and have no previous AID use. Investigators pointed out HbA1c requirements required patients to have an HbA1c less than 12% among basal/bolus or pre-mix insulin users and 7% or more and less than 12% among basal-only users.1

The study cohort had a mean age of 57 (SD, 11) years and 57% were female. The median duration of diabetes was 17 years, the mean HbA1c at screening was 8.2% (SD, 1.4), 62% were currently using CGM, and 25% had never used CGM. Regarding race and ethnicity, 50% of patients were non-Hispanic White, 24% were non-Hispanic Black, 22% were Hispanic or Latino, and 2% were Asian or Pacific Islander.1

Per trial design, participants underwent a 14-day period of standard therapy to collect baseline data, which was followed by a 13-week period where all patients received the Omnipod 5 AID system with the Dexcom G6 continuous glucose monitoring system.1

At the end of the 13 weeks, the mean HbA1c among the cohort decreased from 8.2% (SD, 1.3) at baseline to 7.4% (SD, 0.9) (treatment effect= -0.8%; 95% CI, -1.0 to -0.7; P <.001). When assessing secondary glycemic metrics, results indicated use was associated with a 20% increase in time in range of 70 to 180 mg/dL (4.8 hours per day) and a 20% decrease in time above 180 mg/dL (4.8 hours per day) (P <.001). Investigators pointed out these improvements in time in range were primarily driven by a significant reduction in hyperglycemia with no increase in hypoglycemia.1

When assessing secondary endpoints in a pre-specified hierarchical order, significance was achieved for the first 11 endpoints, including mean glucose, time in range of 70 to 180 mg/dL, time in range of 70 to 140 mg/dL, time at or above 300 mg/dL, time above 250 mg/dL, time above 180 mg/dL, time below 70 mg/dL, time below 54 mg/dL, diabetes distress, percentage with high distress scores, and sleep quality. After the 13-week period with Omnipod 5, 90% of participants indicated they would recommend Omnipod 5 to a friend and 78% of participants expressed interest in continuing use of Omnipod 5 following study conclusion.1

These data demonstrate that simple, easy-to-use AID technology, such as Omnipod 5, can be adopted by a broad population of people with type 2 diabetes and improve their lives, said Trang Ly, MBBS, PhD, senior vice president and medical director at Insulet Corporation.2 A major strength of this study is the diversity of the enrolled population in terms of varying education level, income, ethnicity, and race. These results could have a particularly striking impact among Black and Hispanic people, who experience a higher prevalence of type 2 diabetes and increased mortality rates.

References:

Read more:
Omnipod 5 AID System Proves Benefit for Adults with Type 2 Diabetes - MD Magazine

The Mobi miniature, durable automated insulin patch pump worn on a hikers leg. [Image courtesy of Tandem Diabetes Care] Tandem Diabetes Care (Nasdaq:TNDM) today announced real-world insights highlighting user satisfaction with its Mobi automated insulin pump.

San Diego-basedTandem launched Mobi, the worlds smallest, durable automated insulin delivery (AID) system in the U.S. this year. Itreceived FDA clearance for people with diabetes ages six and up in July 2023. The system pairs with both the Dexcom G6 and G7 CGMs, offering multiple options to patients. Tandem also plans to integrate Mobi (and its t:slim X2 pump) with the Abbott FreeStyle Libre 3 in the future.

Tandem shared a survey on user satisfaction and wearability, finding that 86% of patients reported that they were satisfied or very satisfied with Mobi regardless of prior therapy and agreed that Mobi helps improve their quality of life. The company presented its data at the American Diabetes Association Scientific Sessions in Orlando, Florida.

These real-world user insights provide evidence that we are furthering our mission to improve the lives of people with diabetes by demonstrating that Tandem Mobi not only meets, but exceeds user expectations, said Dr. Jordan Pinsker, chief medical officer at Tandem Diabetes Care. We are proud to share these results at ADA and will continue to innovate to provide the diabetes community with choice and improved quality of life.

In a six-week limited launch survey, the company heard from early users who previously used multiple daily injections (MDI), other insulin pumps (tubed and tubeless) or previous tandem pumps. They exhibited high satisfaction with the wearability features of Mobi combined with the Control-IQ algorithm.

Mobis size enables users to wear it almost anywhere with greater discretion, comfort and flexibility. Control-IQ technology, meanwhile, predicts and helps prevent highs and lows.

For prior pump users, 78% said Mobi reduces diabetes management burden and 88% say its easy to use, while 80% said it delivers more freedom in their lives.

Other data shared at ADA included Mobi users and highlighted improved time in range with no increase in time spent below range. Younger users highlighted form factor, portability, discreteness and wearability as paramount to satisfaction and ongoing use.

Tandem highlighted a number of features contributing to these satisfaction drivers, including a 30-unit minimum fill to reduce insulin waste for those with low insulin requirements. Mobis physical on-pump quick bolus button enables simple, discreet bolusing with programming in grams or unit increments.

On-body wear features a lightweight adhesive sleeve and five-inch tubing, while users can control Mobi from their personal iPhone.

See the rest here:
Tandem reports improved quality of life with Mobi AID system - Drug Delivery Business News